Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK3 | O75914 | 1/20 | 0.56 |
| ▸ | PAK4 | O96013 | 1/20 | 0.56 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.56 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.56 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.56 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.56 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.52 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.52 |
| ▸ | TNK2 | Q07912 | 5/20 | 0.51 |
| ▸ | JAK3 | P52333 | 5/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | WEE1 | P30291 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | CCNK | O75909 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CCND3 | P30281 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1904402 | 0.88 | PAK1 (0.60) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL10192788 | 0.86 | PAK4 (0.65) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL10192787 | 0.85 | PAK3 (0.75) | PAK3PAK4LIMK1LIMK2PAK1 | |
| Hydrochloric Acid SCHEMBL660053 | 0.84 | PAK3 (0.74) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL660213 | 0.79 | JAK3 (0.58) | JAK3CCND3 | |
| SCHEMBL15035152 | 0.78 | PAK1 (0.70) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL15035162 | 0.78 | PAK1 (0.70) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL15035165 | 0.77 | PAK1 (0.67) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL15035147 | 0.76 | PAK1 (0.82) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL5762208 | 0.75 | FGFR1 (0.75) | RIPK2ACVR1NOD2EGFRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2519241-A2 | METHODS FOR TREATING AUTISM | Afraxis, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2011090666-A2 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011090666-A2 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011063415-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063415-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011044537-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044537-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011009097-A2 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011009097-A2 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | PSEN2, MAPT, PSEN1 | PAK3 10/4885PAK4 14/4885LIMK1 206/4885 |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | PAK3 13/4885PAK4 16/4885LIMK1 1000/4885 |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | PAK2, PAK3, PAK4 | PAK3 2/4885PAK4 3/4885LIMK1 298/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | PAK3 5/4885PAK4 6/4885LIMK1 683/4885 |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | CHAT, PSEN2, PAK2 | PAK3 9/4885PAK4 14/4885LIMK1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.